2025
Consensus Guideline for the Management of Malignant Gastrointestinal Obstruction in Patients with Peritoneal Surface Malignancies
Bansal V, Godfrey E, Sadjadi J, Bello R, Kwakman R, Abreu A, Vudatha V, Sparkman B, Freudenberger D, Su D, Turaga K, Micic D, Malec M, Tun S, Polite B, Lambert L, Greenbaum A, Gunderson C, Smith T, Kopecky K, Powers B, Maduekwe U, Ward E. Consensus Guideline for the Management of Malignant Gastrointestinal Obstruction in Patients with Peritoneal Surface Malignancies. Annals Of Surgical Oncology 2025, 1-20. PMID: 40560502, DOI: 10.1245/s10434-025-17362-1.Peer-Reviewed Original ResearchPeritoneal surface malignanciesPalliative care assessmentSurface malignanciesAssess agreement levelsOverall level of evidenceDelphi consensus processGastrointestinal obstructionClinical management pathwaysDecompression tube placementPoor performance statusLevel of evidenceMalignant gastrointestinal obstructionCare assessmentCare EvaluationRound IConsensus processLimited evidencePeritoneal diseaseNational expertsOptimal management strategyPerformance statusClinical guidanceSurgical interventionConsensus guidelinesPoor prognosisPhase 1/2 study of zilovertamab vedotin in pediatric and young adult hematologic malignancies or solid tumors (LIGHTBEAM-U01A).
Kang H, Berlanga P, Campbell-Hewson Q, DuBois S, Koh K, Mauz-Körholz C, Sullivan M, Mangum D, Windsor R, Dickens D, Duarte A, Pashankar F, Ash S, Bellantoni A, Diede S, Singh R, Sidi Y, Yalon M. Phase 1/2 study of zilovertamab vedotin in pediatric and young adult hematologic malignancies or solid tumors (LIGHTBEAM-U01A). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.tps10075.Peer-Reviewed Original ResearchB-cell acute lymphoblastic leukemiaEwing sarcomaPerformance statusAdverse eventsPediatric B-cell acute lymphoblastic leukemiaRefractory to frontline therapyDose of study treatmentDiagnosis of B-cell acute lymphoblastic leukemiaEnd pointsObjective response ratePhase 1/2 studyRadiographically measurable diseaseBone marrow blastsDuration of responseECOG performance statusSecondary end pointsPrimary end pointAdult hematological malignanciesAcute lymphoblastic leukemiaKarnofsky performance statusAntibody-drug conjugatesDose escalationMarrow blastsFrontline therapyOpen-labelTROPION-Lung14: A phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR -mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC).
Lu S, Provencio M, Lisberg A, Mascarenhas E, Tanizaki J, Cheng Y, Kim H, Liu Y, Feng S, Zhang L, Toms L, Yang J, Goldberg S. TROPION-Lung14: A phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR -mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.tps8647.Peer-Reviewed Original ResearchProgression-free survivalSafety run-inCentral nervous systemEGFR mutationsPerformance statusSecondary endpointsPhase 3 clinical trial dataEGFR tyrosine kinase inhibitorsRun-inBlinded independent central reviewEGFR mutated NSCLCEGFR mutation typeDuration of responseWHO performance statusIndependent central reviewPhase 3 studyPrimary study endpointTyrosine kinase inhibitorsTopoisomerase I inhibitorAntibody-drug conjugatesMutated NSCLCAdvanced NSCLCIV diseaseNon-squamousOverall survivalClinicodemographic predictors of enrollment and outcomes in early phase oncology clinical trials in a diverse urban population.
Argulian A, Van Hyfte G, Baldwin E, Kulshrestha A, Lucas N, Wilk J, Wu K, Yuan M, Fazilov G, Fitzgerald L, Hapanowicz O, Osorio M, Cuevas J, Wawrzyniak A, Acuna-Villaorduna A, Zamarin D, Feng D, Galsky M, Marron T, Doroshow D. Clinicodemographic predictors of enrollment and outcomes in early phase oncology clinical trials in a diverse urban population. Journal Of Clinical Oncology 2025, 43: e13514-e13514. DOI: 10.1200/jco.2025.43.16_suppl.e13514.Peer-Reviewed Original ResearchEarly phase clinical trialsOverall survivalPerformance statusAnalyze factors associated with overall survivalFactors associated with overall survivalClinical trialsDose of study therapyDistance to treatment centerUnivariate Cox proportional hazards modelSolid tumor patientsECOG performance statusRetrospective chart reviewEffective novel therapiesPhase clinical trialsCox proportional hazards modelsProportional hazards modelAssociated with decreased likelihoodNon-white raceMedian OSECOG PSStudy therapyT patientsOncology clinical trialsMedian timeTherapeutic optionsImproved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment
Sperduto P, Marqueen K, Chang E, Li J, Davies M, Ebner D, Breen W, Lamba N, Shih H, Edwards D, Kim M, Mahal A, Rahman R, Ankrah N, Boggs D, Lewis C, Hyer D, Buatti J, Johri F, Soliman H, Masucci L, Roberge D, Aneja S, Chiang V, Phuong C, Braunstein S, Dajani S, Sachdev S, Wan Z, Niedzwiecki D, Vaios E, Kirkpatrick J, Pasetsky J, Wang T, Kutuk T, Kotecha R, Ross R, Rusthoven C, Nakano T, Tawbi H, Mehta M. Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment. Journal Of Clinical Oncology 2025, 43: 1910-1919. PMID: 40245362, PMCID: PMC12119226, DOI: 10.1200/jco-24-01351.Peer-Reviewed Original ResearchConceptsGraded Prognostic AssessmentMelanoma brain metastasesPrognostic factorsPrognostic assessmentAbsence of extracranial metastasesGPA 0Multi-institutional retrospective databaseTreatments associated with survivalAnalysis of prognostic factorsMedian follow-up timeModern multimodality therapyKarnofsky performance statusClinical trial eligibilityBrain MetastasesExtracranial metastasesMedian survivalMelanoma patientsMultimodal therapyPerformance statusMultidisciplinary treatmentImproved survivalRetrospective databaseTrial eligibilityTherapeutic modalitiesClinical trialsTime to metastasis after prostatectomy (TTM) and survival outcomes in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of the SWOG 1216 phase 3 trial.
Sayegh N, Jo Y, Swami U, Hage Chehade C, Ozay Z, Gebrael G, Maughan B, Plets M, Hussain M, Dorff T, Lara P, Goldkorn A, Lerner S, Agarwal N. Time to metastasis after prostatectomy (TTM) and survival outcomes in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of the SWOG 1216 phase 3 trial. Journal Of Clinical Oncology 2025, 43: 173-173. DOI: 10.1200/jco.2025.43.5_suppl.173.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression-free survivalOverall survivalMetachronous diseaseMetastatic hormone-sensitive prostate cancerInitial prostate cancer diagnosisTiming of metastatic diseaseHormone-sensitive prostate cancerSubgroups of ptsTime of prostatectomyTime to metastasisCox proportional hazards modelsProstate cancer diagnosisProportional hazards modelDeprivation therapyGleason scoreMetastatic diseaseMetastatic recurrenceMetastatic diagnosisPrognostic factorsPerformance statusProstate cancerPrognostic valueSurvival outcomesProstatectomyTransarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim J, Zhao H, Li C, Madoff D, Ghobrial R, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry A, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel A, Finn R, Llovet J, investigators L. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. The Lancet 2025, 405: 203-215. PMID: 39798578, DOI: 10.1016/s0140-6736(24)02575-3.Peer-Reviewed Original ResearchConceptsEastern Cooperative Oncology GroupNon-metastatic hepatocellular carcinomaProgression-free survivalTreatment-related adverse eventsPembrolizumab groupPhase 3 studyTransarterial chemoembolisationPlacebo groupHepatocellular carcinomaIntention-to-treatOverall survivalDouble-blindPerformance statusAdverse eventsFollow-upEastern Cooperative Oncology Group performance statusChild-Pugh class A diseaseMedian progression-free survivalSolid Tumors version 1.1Blinded independent central reviewA-fetoprotein levelAlbumin-bilirubin gradeResponse Evaluation CriteriaAs-treated populationMedian follow-upPatient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, Schecter J, Vogel M, Lendvai N, Gries K, Katz E, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Filho O, Patel N, Florendo E, Karlin L, Weisel K. Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. The Lancet Haematology 2025, 12: e45-e56. PMID: 39756844, DOI: 10.1016/s2352-3026(24)00320-x.Peer-Reviewed Original ResearchConceptsLenalidomide-refractory multiple myelomaStandard of careVisual analogue scaleMultiple myelomaGlobal health statusPatient-reported outcomesCiltacabtagene autoleucelIntention-to-treat populationLenalidomide-refractory diseaseProgression-free survivalECOG performance statusPhase 3 trialEORTC global health statusWorsening of symptomsClinically meaningful improvementsEuropean Organisation for ResearchEQ-5D-5L visual analogue scaleCilta-celEuroQol 5-Dimension 5-LevelOpen-labelImmunomodulatory drugsMedian agePerformance statusSecondary endpointsClinical efficacy
2024
BIOS-03. CLINICAL PRESENTATION, MANAGEMENT, AND OUTCOME IN NEUROLYMPHOMATOSIS: A SYSTEMATIC REVIEW AND ANALYSIS OF INDIVIDUAL PATIENT DATA FROM 459 CASES
Kaulen L, Hielscher T, Doubrovinskaia S, Hoffmann D, Kessler T, Traub B, Baehring J, Wick W. BIOS-03. CLINICAL PRESENTATION, MANAGEMENT, AND OUTCOME IN NEUROLYMPHOMATOSIS: A SYSTEMATIC REVIEW AND ANALYSIS OF INDIVIDUAL PATIENT DATA FROM 459 CASES. Neuro-Oncology 2024, 26: viii38-viii38. PMCID: PMC11552887, DOI: 10.1093/neuonc/noae165.0151.Peer-Reviewed Original ResearchPeripheral nervous systemPrimary NLPrognostic factorsDiagnostic yieldFDG-PETRituximab-based therapyRituximab-based treatmentMedian overall survivalNon-Hodgkin's lymphomaManifestation of malignancyNervous systemTumor-directed therapyMultivariate survival analysisCox proportional hazards modelsTreatment of NLConcurrent systemic diseaseSystematic reviewProportional hazards modelConsensus therapyPainful polyneuropathyLymphomatous infiltrationOverall survivalPerformance statusPrognostic stratificationClinical presentationDNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial
Iyer G, Tangen C, Sarfaty M, Regazzi A, Lee I, Fong M, Choi W, Dinney C, Flaig T, Thompson I, Lerner S, McConkey D, Rosenberg J. DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. JCO Precision Oncology 2024, 8: e2400287. PMID: 39499893, PMCID: PMC12088707, DOI: 10.1200/po.24.00287.Peer-Reviewed Original ResearchConceptsNeoadjuvant cisplatin-based chemotherapyMuscle-invasive bladder cancerProgression-free survivalDDR alterationsDNA damage response alterationPathological responseBladder cancerDNA damage responseAssociated with pathological responseNeoadjuvant chemotherapy sensitivityPretreatment tumor specimensPathological response rateCisplatin-based chemotherapyDNA damage response genesEstimates of hazard ratiosOverall survivalRadical cystectomyTumor specimensPerformance statusClinical stageChemotherapy sensitivityCox regressionHazard ratioNext-generation sequencingPatientsFeasibility of Multi-Modal Physical Function Data Collection to Assess Treatment Tolerability in Patients with Lymphoma
Paludo J, Dueck A, Bhatnagar V, Brown A, Cathcart-Rake E, Copley D, Diamond M, Faust L, Fiero M, Huntington S, Jeffery M, Jones L, Noble B, Power B, Ritchie J, Ross J, Ruddy K, Schellhorn S, Tarver M, Torre L, Wood W, Gross C, Kluetz P, Thanarajasingam G. Feasibility of Multi-Modal Physical Function Data Collection to Assess Treatment Tolerability in Patients with Lymphoma. Blood 2024, 144: 387-387. DOI: 10.1182/blood-2024-194607.Peer-Reviewed Original ResearchEastern Cooperative Oncology GroupPhysical functionPatient reportsTreatment toleranceCompletion ratesBaseline 6MWTExit surveyInterquartile rangeAssess treatment tolerancePost-treatment follow-upAssessment of PFCooperative Oncology GroupMedian wear timeUnique implementation challengesWearable sensor dataWalk testCytotoxic chemotherapyNon-Hispanic/LatinoNo standard approachOncology GroupAlaska NativesPerformance statusPF measuresFull-time employmentMedian timeA Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy
Hofmeister C, Gupta V, Joseph N, Lonial S, Dhodapkar M, Nooka A, Kaufman J. A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy. Blood 2024, 144: 4672. DOI: 10.1182/blood-2024-203485.Peer-Reviewed Original ResearchAL amyloidosisPlasma cell-directed therapyHigh-sensitivity troponin THematological complete remissionSevere cardiac involvementCell-directed therapiesPoor performance statusMonths of treatmentEnd-stage cardiomyopathyDaratumumab monotherapyComplete remissionCardiac involvementNT-proBNPPerformance statusAmyloid cardiomyopathyTherapeutic optionsSevere cardiomyopathyHeart transplantationStage 3bDirected therapyDiagnosed patientsEuropean trialsClinical consequencesTroponin TTargeted treatmentOral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials
Urrutia S, Sasaki K, Bataller A, Kantarjian H, Montalban-Bravo G, McCloskey J, Griffiths E, Yee K, Zeidan A, Savona M, Oganesian A, Sano Y, Keer H, Garcia-Manero G. Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials. Blood 2024, 144: 661-661. DOI: 10.1182/blood-2024-193274.Peer-Reviewed Original ResearchMedian overall survivalHematopoietic stem cell transplantationHypomethylating agentsTP53 mutationsOverall survivalImproved survivalMedian follow-up timeIPSS-R scoreComplete response rateStem cell transplantationECOG performance statusPropensity score matching analysisFollow-up timeScore matching analysisIPSS-RComplex cytogeneticsCell transplantationPerformance statusDecitabine/cedazuridineTP53wtCo-mutationsLandmark analysisPoor outcomeTP53mutMedian numberImpact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Yates S, Weiss J, Sneider A, Geramita E, Guru Murthy G, Badar T, Im A, Lin C, Cheng W, Winer E, Abaza Y, Litzow M, Atallah E, Swaroop A, Patel A, Shallis R. Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood 2024, 144: 447-447. DOI: 10.1182/blood-2024-207116.Peer-Reviewed Original ResearchDiagnosed AMLAcute myeloid leukemiaEuropean LeukemiaNetOverall survivalComplete responseECOG PSHypomethylating agentsSeverity of presentationMulti-centerPerformance statusRetrospective analysisFactors associated with improved OSTherapy-related acute myeloid leukemiaECOG PS of 2Initiation of induction therapyMultivariate analysisAssociated with worse OSNext generation sequencing panelIntermediate risk diseaseIncomplete count recoveryECOG performance statusDisease biologyNPM1 mutation statusUnivariate Cox modelPre-planned subgroup analysisAssociation of Biologically Effective Dose and Survival in Patients Receiving Head and Neck Stereotactic Body Radiation Therapy
Márquez C, Phan J, Lee A, Reddy J, Garden A, Gunn G, Frank S, Fuller C, Moreno A, Morrison W, Rosenthal D, Spiotto M. Association of Biologically Effective Dose and Survival in Patients Receiving Head and Neck Stereotactic Body Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e770-e771. DOI: 10.1016/j.ijrobp.2024.07.1694.Peer-Reviewed Original ResearchStereotactic body radiation therapyHead and neck cancerBiologically effective doseRadiation therapyPerformance statusN stagePatients treated with stereotactic body radiation therapyTreat recurrent head and neck cancerPatients treated with initial surgeryRecurrent head and neck cancerHigher biologically effective dosesIncreasing BEDMedian follow-up durationAssociated with improved survivalHead and neck cancer patientsEffective doseNo survival improvementSurgically resected patientsNational Cancer DatabaseFractionation schemeAssociated with enhanced survivalCox regression modelsDose escalationHPV statusResected patientsClinical Presentation, Management, and Outcome in Neurolymphomatosis
Kaulen L, Hielscher T, Doubrovinskaia S, Hoffmann D, Kessler T, Traub B, Baehring J, Wick W. Clinical Presentation, Management, and Outcome in Neurolymphomatosis. Neurology 2024, 103: e209698. PMID: 39102613, DOI: 10.1212/wnl.0000000000209698.Peer-Reviewed Original ResearchConceptsPeripheral nervous systemPrimary NLPrognostic factorsDiagnostic yieldFDG-PETMedian overall survivalRituximab-based therapyRituximab-based treatmentNon-Hodgkin's lymphomaManifestation of malignancyNervous systemLog-rank testTumor-directed therapyMultivariate survival analysisCox proportional hazards modelsTreatment of NLConcurrent systemic diseaseIndividual patient dataProportional hazards modelConsensus therapyPainful polyneuropathyLymphomatous infiltrationOverall survivalPerformance statusPrognostic stratificationDevimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study
Philip P, Sahai V, Bahary N, Mahipal A, Kasi A, Lima C, Alistar A, Oberstein P, Golan T, Metges J, Lacy J, Fountzilas C, Lopez C, Ducreux M, Hammel P, Salem M, Bajor D, Benson A, Luther S, Pardee T, Van Cutsem E. Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study. Journal Of Clinical Oncology 2024, 42: 3692-3701. PMID: 39088774, DOI: 10.1200/jco.23.02659.Peer-Reviewed Original ResearchMetastatic pancreatic adenocarcinomaOverall survivalCPI-613Randomized phase III trialTreatment-emergent adverse eventsExperimental armDifficult-to-treat diseaseFavorable performance statusProgression-free survivalTreatment naive patientsFirst-line therapyPhase I studyPhase III trialsMedian OSMetastatic adenocarcinomaIII trialsFirst-linePerformance statusPancreatic adenocarcinomaAdverse eventsDevimistatDay 1Disease progressionControl armPatientsPerformance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy
Mellgard G, Saffran N, Chakrani Z, McCroskery S, Taylor N, Patel M, Liaw B, Galsky M, Oh W, Tsao C, Patel V. Performance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy. American Journal Of Clinical Oncology 2024, 47: 459-464. PMID: 39087466, DOI: 10.1097/coc.0000000000001115.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerPerformance statusProstate cancerOverall survivalAndrogen receptor-targeted therapiesCompare overall survivalReceptor-targeted therapyReduced performance statusSingle-institution studyCompare baseline characteristicsAssessment of PSFisher's exact testWilcoxon signed-rank testTaxane chemotherapyShorter OSCompare OSSigned-rank testTargeted therapyTreatment courseAndrogen receptorBaseline characteristicsExact testCox regressionART treatmentImpact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer
Skelton W, Masur J, Thomas J, Fallah P, Jain R, Ravi P, Mantia C, McGregor B, Nuzzo P, Adib E, Zarif T, Preston M, Clinton T, Li R, Steele G, Kassouf W, Freeman D, Pond G, Jain R, Sonpavde G. Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. Clinical Genitourinary Cancer 2024, 22: 102143. PMID: 39032202, DOI: 10.1016/j.clgc.2024.102143.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerPathological complete responsePathologic complete response rateRenin-angiotensin systemNeoadjuvant chemotherapyAngiotensin-converting enzyme inhibitorsConverting enzyme inhibitorsOverall survivalRadical cystectomyPerformance statusClinical stageComplete responseBladder cancerAssociated with increased pCRAssociated with pathologic complete responseFemale sexAssociated with improved OSImpact of angiotensin-converting enzyme inhibitorsCycles of neoadjuvant chemotherapyMuscle invasive bladder cancerClinical stage of diseaseEnzyme inhibitorsAssociated with OSInitiation of therapyInvasive bladder cancerCorrelation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study.
Swami U, Jo Y, Narang A, Plets M, Hage Chehade C, Gebrael G, Gupta S, Myint Z, Tangen C, Lara P, Thompson I, Hussain M, Dorff T, Lerner S, Agarwal N. Correlation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study. Journal Of Clinical Oncology 2024, 42: 5081-5081. DOI: 10.1200/jco.2024.42.16_suppl.5081.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerBody mass indexBody mass index cohortZubrod performance statusCorrelation of body mass indexPhase III studyOverall survivalSurvival outcomesGleason scoreIII studiesPerformance statusProstate cancerMetastatic hormone-sensitive prostate cancer settingAssociated with improved survival outcomesMetastatic castration-resistant prostate cancerMultivariate analysisHormone-sensitive prostate cancerAssociated with better OSRandomized phase III studyCastration-resistant prostate cancerNormal body mass indexCategorized body mass indexPrognostication of patientsAssociation of obesityDisease burden
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply